ClinicalTrials.gg
CompletedNCT01439204Updated Mar 19, 2014Results posted

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

A Phase 1 interventional study of Abatacept (BMS-188667) in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
22nd of 63
223 · median 119
Started
2011
with 4 others
Phase 1
8 of 63
none open now
Registered
30th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 22nd largest by enrollment, is one of 5 that started in 2011, is one of 8 in phase 1, and was the 30th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the blood levels of Abatacept (BMS-188667) drug product manufactured at Lonza Biologics and the Devens, MA facility of Bristol-Myers Squibb are comparable in healthy subjects

Read the detailed description

Primary Purpose of this study is to compare the pharmacokinetic (PK) of Abatacept (BMS-188667) manufactured at Lonza relative to Abatacept (BMS-188667) manufactured at Devens, MA facility following a single intravenous infusion of 750 mg in healthy subjects

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, (ECGs), and clinical laboratory determinations
  • Body weight will be between 60 and 100 kg, inclusive

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Any major surgery within 4 weeks of study drug administration
  • Smoking more than 10 cigarettes per day
  • Recent (within 6 months of study drug administration) drug or alcohol abuse.
  • Positive blood screen for antibody, surface antigen, or -1, Human Immunodeficiency Virus-2 antibody
  • History of any significant drug allergy or asthma
  • Women who are pregnant or breastfeeding and/or unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Active comparator
    Abatacept (BMS-188667) manufactured at Lonza, NH facility

    Biological: Abatacept (BMS-188667)

  • Experimental
    Abatacept (BMS-188667) manufactured at Devens, MA facility

    Biological: Abatacept (BMS-188667)

Interventions

  • Solution for injection, Intravenous, 750 mg, Single dose, 1 day,

    Also known as: BMS-188667

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    Cmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). Cmax was measured in micro grams per milliliter (µg/mL).

    Time frame: Days 1 to 71

  2. Time to Reach Maximum Concentration (Tmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    Tmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). Tmax was measured in hours (h).

    Time frame: Day 1 to Day 71

  3. Area Under the Concentration-time Curve (AUC) From Time Zero to 28 Days [AUC(0-28 Days)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    AUC (0 - 28) was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). AUC (0 - 28) was measured in micro grams\*hours per milliliter (µg\*h/mL).

    Time frame: Day 1 to Day 71

  4. Area Under the Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration [AUC(0-T)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    AUC (0 - T) was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). AUC (0 - T) was measured in micro grams\*hour per milliliter (µg\*h/mL).

    Time frame: Day 1 to Day 71

  5. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity [AUC(0 - INF)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    AUC (0 - INF) was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). AUC (0 - INF) was measured in µg\*h/mL.

    Time frame: Day 1 to Day 71

  6. Terminal Phase Elimination Half-life (T-HALF) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    T-HALF was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). T-HALF was measured in hours (h).

    Time frame: Day 1 to Day 71

  7. Total Body Clearance (CLT) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    CLT was the volume of abatacept cleared by the system, normalized by baseline body weight. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). CLT was measured in milliliters per hours per kilogram of body weight (mL/h/kg).

    Time frame: Day 1 to Day 71

  8. Volume of Distribution at Steady-state (Vss) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

    Vss was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). Vss was measured in liters per kg body weight (L/kg).

    Time frame: Day 1 to Day 71

Secondary outcomes

  1. Number of Participants With Positive Abatacept-induced Immunogenicity Response

    Immunogenicity determination was based on titers of anti-abatacept and anti- cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4-T) antibodies in serum over time. A participant had a positive abatacept-induced immunogenicity if 1 of the following criteria were met: missing baseline measurement and a positive response after baseline; negative baseline response and positive response after baseline; a baseline response and a positive response after baseline that has a titer value strictly greater than the baseline titer value. A validated, sensitive, electrochemiluminescence assay (ECL) method was used to analyze the antibodies in serum. Samples confirmed positive with ECL and with abatacept serum concentrations of less than equal to 1 µg/mL were further analyzed with a validated, in vitro, cell-based bioassay to analyze the sera containing the abatacept neutralizing activity. Samples obtained on Days 29, 57 and 71 post dose of abatacept on Day 1 (baseline).

    Time frame: Days 29, 57, 71

  2. Number of Participants With Marked Serum Chemistry Abnormalities on Days 2, 15, 29, 57 and 71 - Safety Population

    Blood samples obtained: Days 1, 2, 4, 8, 15, 22, 29, 43, 57 and 71. International Units per liter (U/L); milligram per deciliter (mg/dL); Male(M); Female (F). Reference ranges (low/high) for laboratories for which participants were identified with marked abnormalities during the study: Blood Urea Nitrogen (M/F) 10-20mg/dL ; Creatine Kinase (F) 21-21 U/L,(M) 32-294 U/L; Direct Bilirubin (M/F) 0.1-0.4 mg/dL ; Fasting Glucose (M/F) 70-110 mg/dL; Lactate Dehydrogenase (M/F) 110-209 U/L.

    Time frame: Day 2 to Day 71

  3. Number of Participants With Marked Hematology Abnormalities on Days 2, 15, 29, 57, and 71 - Safety Population

    Blood samples obtained: Days 2, 4, 8, 15, 22, 29, 43, 57 and 71. Male(M); Female (F). Reference ranges (low/high) for laboratory parameters for which participants were identified with marked abnormalities during the study: Leukocytes (quantitative White blood cells) (M/F) 4-11\*10\^3/microliters (µL); Neutrophils (absolute)(M/F) 1.4- 8.2\*10\^3/µL.

    Time frame: Day 2 to Day 72

  4. Change From Baseline in Systolic Blood Pressure - Safety Population

    Blood pressure was obtained while the participant had been quietly seated for at least 5 minutes. Baseline was the 0 hour measurement on Day 1 (day of dosing) or if this value was missing, the last measurement before dosing. Blood pressure was measured in millimeters of mercury (mmHg) on Days 1, 2, 15, 29, 57, and 71.

    Time frame: Day 1 to Day 71

  5. Change From Baseline in Diastolic Blood Pressure on Days 1, 2, 15, 29, 57, and 71 - Safety Population

    Blood pressure was obtained while the participant had been quietly seated for at least 5 minutes. Baseline was the 0 hour measurement on Day 1 (day of dosing) or if this value was missing, the last measurement before dosing. Blood pressure was measured in millimeters of mercury (mmHg) on Days 1, 2, 15, 29, 57, and 71.

    Time frame: Day 1 to Day 71

  6. Number of Participants With a Change From Baseline in QT Interval and Corrected (Fridericia) QT Interval (QTcF) - Safety Population

    12-lead electrocardiograms were performed on a supine participant (5 minutes supine) at baseline (baseline = screening; Days -21 to -2) and at Day 71. QT interval and QTc were measured in mille seconds (msec). A change from baseline QT and QTc (corrected for heart rate by Fridericia formula) greater than (\>) 30 msec or less than (\<) 60 msec were presented, as well as values over 450 and 500 msec. QT interval on ECG image defined as: time from the beginning of the QRS (complex consisting of Q, R and S waves) to the end of the T wave.

    Time frame: Day 1 to Day 71

07

Results

Posted Feb 4, 2014

Participant flow

10 October 2011 to 11 Feb 2012. Participants who were randomized to an arm were admitted to a clinical facility the day prior to dosing (Day -1) and confined until 24 hours post the single dose; participants followed to Day 71.

Participant flow — Overall Study
Milestone750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Started3636
Completed3233
Not completed43
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up02
Withdrew: No longer meets study criteria10
Withdrew: Poor/non-compliance30

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

Cmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). Cmax was measured in micro grams per milliliter (µg/mL).

Time frame:
Days 1 to 71
Reported as:
Geometric mean · µg/mL
Maximum Observed Concentration (Cmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population
µg/mL750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Maximum Observed Concentration (Cmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population262 ± 27255 ± 21
PrimaryTime to Reach Maximum Concentration (Tmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

Tmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). Tmax was measured in hours (h).

Time frame:
Day 1 to Day 71
Reported as:
Median · h
Time to Reach Maximum Concentration (Tmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population
h750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Time to Reach Maximum Concentration (Tmax) of Single Dose Abatacept - Pharmacokinetic Evaluable Population1.00 (0.55 to 2.12)1.00 (1.00 to 6.00)
PrimaryArea Under the Concentration-time Curve (AUC) From Time Zero to 28 Days [AUC(0-28 Days)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population

AUC (0 - 28) was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). AUC (0 - 28) was measured in micro grams\*hours per milliliter (µg\*h/mL).

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · µg*h/mL
Area Under the Concentration-time Curve (AUC) From Time Zero to 28 Days [AUC(0-28 Days)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population
µg*h/mL750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Area Under the Concentration-time Curve (AUC) From Time Zero to 28 Days [AUC(0-28 Days)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population33195 ± 2635255 ± 23
PrimaryArea Under the Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration [AUC(0-T)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population

AUC (0 - T) was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). AUC (0 - T) was measured in micro grams\*hour per milliliter (µg\*h/mL).

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · µg*h/mL
Area Under the Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration [AUC(0-T)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population
µg*h/mL750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Area Under the Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration [AUC(0-T)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population39295 ± 2341916 ± 25
PrimaryArea Under the Concentration-time Curve From Time Zero Extrapolated to Infinity [AUC(0 - INF)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population

AUC (0 - INF) was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). AUC (0 - INF) was measured in µg\*h/mL.

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · µg*h/mL
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity [AUC(0 - INF)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population
µg*h/mL750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity [AUC(0 - INF)] of Single Dose Abatacept - Pharmacokinetic Evaluable Population40385 ± 2343229 ± 27
PrimaryTerminal Phase Elimination Half-life (T-HALF) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

T-HALF was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). T-HALF was measured in hours (h).

Time frame:
Day 1 to Day 71
Reported as:
Mean · h
Terminal Phase Elimination Half-life (T-HALF) of Single Dose Abatacept - Pharmacokinetic Evaluable Population
h750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Terminal Phase Elimination Half-life (T-HALF) of Single Dose Abatacept - Pharmacokinetic Evaluable Population344 ± 87.6364 ± 106
PrimaryTotal Body Clearance (CLT) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

CLT was the volume of abatacept cleared by the system, normalized by baseline body weight. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). CLT was measured in milliliters per hours per kilogram of body weight (mL/h/kg).

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · mL/h/kg
Total Body Clearance (CLT) of Single Dose Abatacept - Pharmacokinetic Evaluable Population
mL/h/kg750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Total Body Clearance (CLT) of Single Dose Abatacept - Pharmacokinetic Evaluable Population0.237 ± 240.219 ± 24
PrimaryVolume of Distribution at Steady-state (Vss) of Single Dose Abatacept - Pharmacokinetic Evaluable Population

Vss was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: predose (0 hours), 0.25 hours (h), 0.5, 1, 2, 6, 12, 24, 72, 168, 336, 504, 672, 1008, 1344, and 1688 h post dose (Days 1 to 71). The results were summarized. The lower limit of assay quantitation (LLOQ) was 1.00 nanograms per milliliter (ng/mL). Vss was measured in liters per kg body weight (L/kg).

Time frame:
Day 1 to Day 71
Reported as:
Geometric mean · L/kg
Volume of Distribution at Steady-state (Vss) of Single Dose Abatacept - Pharmacokinetic Evaluable Population
L/kg750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Volume of Distribution at Steady-state (Vss) of Single Dose Abatacept - Pharmacokinetic Evaluable Population0.088 ± 330.083 ± 22
SecondaryNumber of Participants With Positive Abatacept-induced Immunogenicity Response

Immunogenicity determination was based on titers of anti-abatacept and anti- cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4-T) antibodies in serum over time. A participant had a positive abatacept-induced immunogenicity if 1 of the following criteria were met: missing baseline measurement and a positive response after baseline; negative baseline response and positive response after baseline; a baseline response and a positive response after baseline that has a titer value strictly greater than the baseline titer value. A validated, sensitive, electrochemiluminescence assay (ECL) method was used to analyze the antibodies in serum. Samples confirmed positive with ECL and with abatacept serum concentrations of less than equal to 1 µg/mL were further analyzed with a validated, in vitro, cell-based bioassay to analyze the sera containing the abatacept neutralizing activity. Samples obtained on Days 29, 57 and 71 post dose of abatacept on Day 1 (baseline).

Time frame:
Days 29, 57, 71
Reported as:
Number · participants
Number of Participants With Positive Abatacept-induced Immunogenicity Response
participants750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Number of Participants With Positive Abatacept-induced Immunogenicity Response41
SecondaryNumber of Participants With Marked Serum Chemistry Abnormalities on Days 2, 15, 29, 57 and 71 - Safety Population

Blood samples obtained: Days 1, 2, 4, 8, 15, 22, 29, 43, 57 and 71. International Units per liter (U/L); milligram per deciliter (mg/dL); Male(M); Female (F). Reference ranges (low/high) for laboratories for which participants were identified with marked abnormalities during the study: Blood Urea Nitrogen (M/F) 10-20mg/dL ; Creatine Kinase (F) 21-21 U/L,(M) 32-294 U/L; Direct Bilirubin (M/F) 0.1-0.4 mg/dL ; Fasting Glucose (M/F) 70-110 mg/dL; Lactate Dehydrogenase (M/F) 110-209 U/L.

Time frame:
Day 2 to Day 71
Reported as:
Number · participants
Number of Participants With Marked Serum Chemistry Abnormalities on Days 2, 15, 29, 57 and 71 - Safety Population
participants750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Creatine Kinase (high) Day 2 (N=36)10
Creatine Kinase (high) Day 15 (N=36,34)10
Creatine Kinase (high) Day 29 (N=34,33)21
Creatine Kinase (high) Day 57 (N=31,33)11
Creatine Kinase (high) Day 71 (N=36,34)12
Lactate Dehydrogenase (high) Day 2 (N=36)01
Blood urea nitrogen (high) Day 15 (N=36,34)10
Blood urea nitrogen (high) Day 29 (N=34)01
Blood urea nitrogen (high) Day 71 (N=36,34)20
Bilirubin Direct (high) Day 29 (N=34)03
Bilirubin Direct (high) Day 71 (N=36,34)01
Fasting Glucose (high) Day 71 (N=36,34)10
SecondaryNumber of Participants With Marked Hematology Abnormalities on Days 2, 15, 29, 57, and 71 - Safety Population

Blood samples obtained: Days 2, 4, 8, 15, 22, 29, 43, 57 and 71. Male(M); Female (F). Reference ranges (low/high) for laboratory parameters for which participants were identified with marked abnormalities during the study: Leukocytes (quantitative White blood cells) (M/F) 4-11\*10\^3/microliters (µL); Neutrophils (absolute)(M/F) 1.4- 8.2\*10\^3/µL.

Time frame:
Day 2 to Day 72
Reported as:
Number · participants
Number of Participants With Marked Hematology Abnormalities on Days 2, 15, 29, 57, and 71 - Safety Population
participants750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Any marked abnormalities Day 2 (N=36)00
Any marked abnormalities Day 15 (n=36,34)00
Leukocytes (high) Day 29 (N=34,33)01
Leukocytes (high) Day 57 (N=31,33)01
Leukocytes (high) Day 71 (N=36,34)11
Neutrophils (absolute) (high) Day 71 (N=36,34)11
SecondaryChange From Baseline in Systolic Blood Pressure - Safety Population

Blood pressure was obtained while the participant had been quietly seated for at least 5 minutes. Baseline was the 0 hour measurement on Day 1 (day of dosing) or if this value was missing, the last measurement before dosing. Blood pressure was measured in millimeters of mercury (mmHg) on Days 1, 2, 15, 29, 57, and 71.

Time frame:
Day 1 to Day 71
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure - Safety Population
mmHg750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Day 1 (1 hour post dose) (N=36)-6.3 ± 9.73-4.5 ± 9.06
Day 2 (N=36)-3.0 ± 12.31-1.4 ± 10.35
Day 15 (N=36,34)-1.1 ± 12.090.3 ± 8.12
Day 29 (N=33)-2.3 ± 10.94-0.2 ± 9.65
Day 57 (N=31,33)1.0 ± 11.963.4 ± 9.48
Day 71 (N=36,34)2.2 ± 12.092.9 ± 9.87
SecondaryChange From Baseline in Diastolic Blood Pressure on Days 1, 2, 15, 29, 57, and 71 - Safety Population

Blood pressure was obtained while the participant had been quietly seated for at least 5 minutes. Baseline was the 0 hour measurement on Day 1 (day of dosing) or if this value was missing, the last measurement before dosing. Blood pressure was measured in millimeters of mercury (mmHg) on Days 1, 2, 15, 29, 57, and 71.

Time frame:
Day 1 to Day 71
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure on Days 1, 2, 15, 29, 57, and 71 - Safety Population
mmHg750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Day 1 (1 hour post dose) N=36-4.9 ± 5.91-4.1 ± 5.78
Day 2 (N=36)-2.3 ± 8.98-0.6 ± 6.02
Day 15 (N=36,34)-1.4 ± 7.451.0 ± 7.29
Day 29 (N=33)-1.9 ± 6.370.9 ± 7.08
Day 57 (N=31,33)0.4 ± 7.483.5 ± 7.56
Day 71 (N=36,34)1.6 ± 8.594.0 ± 5.78
SecondaryNumber of Participants With a Change From Baseline in QT Interval and Corrected (Fridericia) QT Interval (QTcF) - Safety Population

12-lead electrocardiograms were performed on a supine participant (5 minutes supine) at baseline (baseline = screening; Days -21 to -2) and at Day 71. QT interval and QTc were measured in mille seconds (msec). A change from baseline QT and QTc (corrected for heart rate by Fridericia formula) greater than (\>) 30 msec or less than (\<) 60 msec were presented, as well as values over 450 and 500 msec. QT interval on ECG image defined as: time from the beginning of the QRS (complex consisting of Q, R and S waves) to the end of the T wave.

Time frame:
Day 1 to Day 71
Reported as:
Number · participants
Number of Participants With a Change From Baseline in QT Interval and Corrected (Fridericia) QT Interval (QTcF) - Safety Population
participants750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MA
Change from baseline in QT >60 msec01
Change from baseline in QT >30 msec < 60 msec54
Change from baseline in QTc >60 msec00
Change from baseline in QTc >30 msec < 60 msec22
QT > 500 msec00
QT > 450 msec01
QTcF >450 msec00

Adverse events

Collected over Day 1 to Day 71. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
750 mg Abatacept From Devens, MA—0/36 (0%)11/36 (30.6%)
750 mg Abatacept From Lonza, NH—0/36 (0%)12/36 (33.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
Event750 mg Abatacept From Devens, MA750 mg Abatacept From Lonza, NH
HeadacheNervous system disorders5/366/36
CoughRespiratory, thoracic and mediastinal disorders2/364/36
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/362/36
Nasal congestionRespiratory, thoracic and mediastinal disorders3/360/36
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/363/36
DiarrhoeaGastrointestinal disorders2/361/36
DizzinessNervous system disorders2/362/36
Back painMusculoskeletal and connective tissue disorders0/362/36
Vision blurredEye disorders0/362/36
Upper respiratory tract infectionInfections and infestations1/362/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MATotal
Mean31.6 ± 10.0231.2 ± 8.9031.4 ± 9.41
Sex: Female, Male
Sex: Female, Male(Participants)750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MATotal
Female222143
Male141529
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MATotal
Hispanic or Latino4610
Not Hispanic or Latino323062
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MATotal
United States363672
Body Weight
Body Weight(kg)750 mg Abatacept From Lonza, NH750 mg Abatacept From Devens, MATotal
Mean78.93 ± 11.47279.39 ± 11.05779.16 ± 11.189
08

Study locations

1 site
  • Icon Clinical Pharmacology Unit, Llc
    Omaha, Nebraska 68154, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Sep 23, 2011
Start
Oct 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Feb 4, 2014
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01439204
Responsible party
Sponsor
First posted
Sep 23, 2011
Start date
Oct 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Feb 4, 2014
Last update
Mar 19, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion